- Home
- AIRS vs CLLS Comparison
AIRS vs CLLS Comparison
Compare AIRS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- CLLS
- Stock Information
- Founded
- AIRS 2012
- CLLS 1999
- Country
- AIRS United States
- CLLS France
- Employees
- AIRS N/A
- CLLS N/A
- Industry
- AIRS Medical/Nursing Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- CLLS Health Care
- Exchange
- AIRS Nasdaq
- CLLS Nasdaq
- Market Cap
- AIRS 166.3M
- CLLS 143.4M
- IPO Year
- AIRS 2021
- CLLS 2007
- Fundamental
- Price
- AIRS $5.42
- CLLS $1.61
- Analyst Decision
- AIRS Hold
- CLLS Buy
- Analyst Count
- AIRS 3
- CLLS 1
- Target Price
- AIRS $3.75
- CLLS $4.00
- AVG Volume (30 Days)
- AIRS 781.4K
- CLLS 52.1K
- Earning Date
- AIRS 08-08-2025
- CLLS 08-05-2025
- Dividend Yield
- AIRS N/A
- CLLS N/A
- EPS Growth
- AIRS N/A
- CLLS N/A
- EPS
- AIRS N/A
- CLLS N/A
- Revenue
- AIRS $172,101,000.00
- CLLS $54,747,000.00
- Revenue This Year
- AIRS N/A
- CLLS $48.52
- Revenue Next Year
- AIRS $4.90
- CLLS $5.17
- P/E Ratio
- AIRS N/A
- CLLS N/A
- Revenue Growth
- AIRS N/A
- CLLS 351.26
- 52 Week Low
- AIRS $1.53
- CLLS $1.10
- 52 Week High
- AIRS $9.20
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- AIRS 64.24
- CLLS 61.29
- Support Level
- AIRS $4.70
- CLLS $1.56
- Resistance Level
- AIRS $5.65
- CLLS $1.49
- Average True Range (ATR)
- AIRS 0.35
- CLLS 0.09
- MACD
- AIRS -0.01
- CLLS 0.02
- Stochastic Oscillator
- AIRS 77.42
- CLLS 86.67
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.